Antiplatelet Drugs in Primary and Secondary Prevention of Atherothrombotic Events

Silva, Marcos Vinícius Ferreira; Dusse, Luci Maria Sant’Ana; Vieira, Lauro Mello; Carvalho, Maria das Graças

doi:10.5935/abc.20130122

Cited by 8 publications

(9 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The detached plaque and the resulting thrombus may enter the systemic circulation and cause occlusion of blood vessels, thereby limiting blood supply to organs such as the heart (myocardial infarction) or the brain (stroke). Thus, inhibition of platelet activity is an important strategy to prevent such thrombotic events [ 61 , 62 ].…”

Section: Cardioprotective Effects Of Stilbenoidsmentioning

confidence: 99%

Biological Activities of Stilbenoids

Akinwumi

Bordun

Anderson

2018

IJMS

271

243

View full text Add to dashboard Cite

Stilbenoids are a group of naturally occurring phenolic compounds found in various plant species. They share a common backbone structure known as stilbene, but differ in the nature and position of substituents. Stilbenoids are classified as phytoalexins, which are antimicrobial compounds produced de novo in plants to protect against fungal infection and toxins. In this review, the biological effects of stilbenoids such as resveratrol, pterostilbene, gnetol and piceatannol are discussed. Stilbenoids exert various biological activities ranging from cardioprotection, neuroprotection, anti-diabetic properties, depigmentation, anti-inflammation, cancer prevention and treatment. The results presented cover a myriad of models, from cell culture to animal studies as well as clinical human trials. Although positive results were obtained in most cell culture and animal studies, further human studies are needed to substantiate beneficial effects of stilbenoids. Resveratrol remains the most widely studied stilbenoid. However, there is limited information regarding the potential of less common stilbenoids. Therefore, further research is warranted to evaluate the salutary effects of various stilbenoids.

show abstract

Section: Cardioprotective Effects Of Stilbenoidsmentioning

confidence: 99%

Biological Activities of Stilbenoids

Akinwumi

Bordun

Anderson

2018

IJMS

271

243

View full text Add to dashboard Cite

show abstract

“…For this reason, inhibition of platelet activity is a vital strategy to prevent this thrombotic consequence. [39] Resveratrol has been shown to inhibit platelet aggregation in both human and animal studies. In addition, an in vitro study of resveratrol (50 mcg/mL) indicated that it inhibited platelet aggregation caused by collagen, epinephrine, and thromboxane, and these effects were attributed to cyclooxygenase (COX-1) suppression on the arachidonic acid pathway.…”

Section: Platelet Aggregationmentioning

confidence: 99%

The effects of resveratrol on human health

Aydın

Erbaş

2020

FNG & Demiroğlu Bilim Tıp Dergisi

View full text Add to dashboard Cite

Resveratrol is a phytochemical found in about 72 plants in nature. Among them, Polygonum cuspidatum is the most important, and is especially abundant in the skin of colorful grape varieties. Resveratrol is used in the prevention and treatment of various diseases. With its polyphenolic structure, it has antioxidant activity and can reduce the risk of heart disease by preventing platelet aggregation and LDL oxidation. It is also known to prevent cell death. In addition, some studies have demonstrated its positive effects on Alzheimer's, diabetes, obesity, and cancer. Since the scientific data in humans is limited, studies on the effects on physiological and pathological conditions and potential protective effects against diseases are still ongoing. This article examines and reviews the results of studies on the protective effects of resveratrol on the body and tissues.

show abstract

“…Due to the key role performed by platelets in pathogenesis of atherothrombotic events, using antiplatelet agents is of the essence for primary and secondary prevention of cardiovascular events. 9 However, although the use of antiplatelet agents has increased cardiovascular safety of many patients, 10 when they need a non-cardiac surgery, surgeons and anesthesiologists frequently have to face the decision of whether to interrupt or not antiplatelet therapy in those patients during the perioperative period considering the risks of the occurrence of thrombi or bleedings, respectively. 11 - 13 …”

Section: Introductionmentioning

confidence: 99%

Factors Associated with Inadequate Management of Antiplatelet Agents in Perioperative Period of Non-Cardiac Surgeries

Borges¹,

Almeida²,

Filho³

et al. 2018

Arquivos Brasileiros De Cardiologia

View full text Add to dashboard Cite

BackgroundThe current guidelines dispose recommendations to manage antiplatelet agents in the perioperative period; however, the daily medical practices lack standardization.ObjectivesTo asses factors associated with inadequate management of antiplatelet agents in the perioperative period of non-cardiac surgeries.MethodsCross-sectional Study conducted in hospital from October 2014 to October 2016. The study dependent variable was a therapy that did not comply with the recommendations in the Brazilian Association of Cardiology (SBC) guidelines. The independent variables included some characteristics, the people in charge of the management and causes of lack of adherence to those guidelines. Variables were included in the multivariate model. Analysis was based on the odds ratio (OR) value and its respective 95% confidence interval (CI) estimated by means of logistic regression with 5% significance level.ResultsThe sample was composed of adult patients submitted to non-cardiac surgeries and who would use acetylsalicylic acid (aspirin) or clopidogrel (n = 161). The management failed to comply with the recommendations in the guidelines in 80.75% of the sample. Surgeons had the highest number of noncomplying orientations (n = 63). After multivariate analysis it was observed that patients with a higher level of schooling (OR = 0.24; CI95% 0.07-0.78) and those with a previous episode of acute myocardial infarction (AMI) (OR = 0.18; CI95% 0.04-0.95) had a higher probability of using a therapy complying with the guidelines.ConclusionPositive association between patients’ schooling level, or those with a history of previous AMI, with management of the use of aspirin and clopidogrel in the perioperative period of non-cardiac surgeries. However, diverging conducts stress the need of having internal protocol defined.

show abstract

Antiplatelet Drugs in Primary and Secondary Prevention of Atherothrombotic Events

Cited by 8 publications

References 19 publications

Biological Activities of Stilbenoids

Biological Activities of Stilbenoids

The effects of resveratrol on human health

Factors Associated with Inadequate Management of Antiplatelet Agents in Perioperative Period of Non-Cardiac Surgeries

Contact Info

Product

Resources

About